Free Trial

Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market

Cytokinetics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • MYQORZO’s launch is gaining momentum: Revenue rose 76% quarter over quarter, patient dispenses exceeded 2,800, and the drug reached nearly 45% of new-to-brand prescriptions after eight months. Coverage has also improved, including 90% of Medicare lives at parity with CAMZYOS.
  • Cytokinetics plans to expand aficamten’s reach: The company expects to submit an application based on the MAPLE-HCM study shortly and seek approval for non-obstructive HCM by year-end, with a European submission planned for early 2027. Approval is required before any nHCM launch.
  • Funding supports the growth plans, but trial safety remains relevant: Cytokinetics ended the quarter with $1.6 billion in cash and investments and sees a possible path to cash-flow positivity in two to two-and-a-half years. The company also addressed an imbalance in heart failure events during ACACIA-HCM titration, which it said was not repeated in FOREST-HCM.
  • MarketBeat previews top five stocks to own in December.

Cytokinetics NASDAQ: CYTK executives said the launch of its heart drug MYQORZO is gaining prescribers and market share as the company prepares regulatory submissions that could expand use of aficamten, the drug’s active ingredient.

Chief Business Officer Isaac Ciechanover said revenue rose 76% from the second quarter, while patient dispenses exceeded 2,800, up from 1,500. He said the cardiac myosin inhibitor market grew 45% year over year.

Chief Financial Officer Sung Lee said MYQORZO had reached close to 45% new-to-brand prescription share after eight months on the market. The company has not provided a longer-term share target, but executives said they expect continued growth as more prescribers and health systems adopt the drug.

Prescriber adoption and access

Jeff Lotz, senior vice president of U.S. sales and operations, attributed adoption in part to MYQORZO’s dosing and monitoring flexibility compared with CAMZYOS. He said physicians are using the full two-to-eight-week titration and monitoring window, with the average currently around four to six weeks.

Lotz said the company has gained interest among community cardiologists who had not previously prescribed a cardiac myosin inhibitor, partly because they may have fewer staff than specialized clinics. Across its prescriber group, productivity has grown to about four patients per doctor on average, he said. Higher-volume users average seven patients, while previously inexperienced prescribers have increased from one to two.

More than 3,000 health care professionals are certified under the drug’s risk evaluation and mitigation strategy, or REMS, Lotz said. About two-thirds are prescribing or affiliated with a prescriber in the same clinic. The remaining third represents an opportunity, although certification does not necessarily mean a clinician will write prescriptions, he said.

Lotz said access has improved, with 90% of Medicare lives covered at parity with CAMZYOS and commercial coverage at 60%, up from 50% a quarter earlier. Some plans still have new-to-market blocks, but he expects access to improve into 2027. Switching from CAMZYOS has remained in the mid-single digits as a percentage of the launch, he said, and is not a company focus.

Expansion plans and trial safety

Ciechanover said Cytokinetics planned to submit a supplemental application based on the MAPLE-HCM study the following week and an application for non-obstructive hypertrophic cardiomyopathy, or nHCM, by year-end. He also cited an expected European submission in early 2027.

Any nHCM launch would require approval. Chief Medical Officer Steve Heitner said the company hopes to use evidence from the ACACIA-HCM and FOREST-HCM studies to seek monitoring and titration provisions similar to those for obstructive HCM, where possible.

Heitner addressed an imbalance in heart failure events during ACACIA-HCM: 12 patients developed heart failure during titration, compared with three placebo patients who developed it later in the study. He said the same pattern was not seen during the comparable titration period in FOREST-HCM and attributed the difference to physician-guided dosing there, compared with computer-driven titration in ACACIA.

Lotz said the company expects a potential nHCM launch to follow a cadence similar to the obstructive launch. Adoption could be faster among experienced prescribers, he said, but Cytokinetics still needs to educate the market about the disease.

Long-term plans

Cytokinetics is gathering longer-term safety and efficacy data through studies including ASPEN and FOREST-HCM. Heitner said a principal aim of ASPEN is to collect real-world data that could support an eventual easing of REMS requirements.

Lee said the company ended the latest quarter with $1.6 billion in cash and investments, which it expects to use for the U.S. launch, upcoming European launches and pipeline development. He said there are scenarios in which Cytokinetics could become cash-flow positive in two to two-and-a-half years, depending in the near term on the trajectory of its obstructive HCM business.

About Cytokinetics (NASDAQ:CYTK)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company's work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cytokinetics Right Now?

Before you consider Cytokinetics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.

While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines